Pamlico BioPharma, Inc. develops fully-human monoclonal antibodies (hmAb) for the rapid diagnosis and treatment of infectious diseases and cancer. Pamlico’s lead program is focused on severe pneumonia caused by Streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. Pamlico was founded on technologies from the Oklahoma Medical Research Foundation (OMRF) and from Emory University, and is anticipated to enter clinical trials in late 2015.
Pamlico has partnered with Accele BioPharma, Inc., a biotechnology accelerator. Accele Venture Partners has provided seed capital to Pamlico to fund initial development milestones. Pamlico is supported by strong intellectual property, has shown early success in validated preclinical models, and has significant commercial potential in the field of infectious diseases. Accele BioPharma is interested in discussing this program and related intellectual property with investors and relevant commercialization partners. Visit Accele BioPharma’s website for more information.